Showing 8141-8150 of 9427 results for "".
- BTL Vanquish FDA Cleared for Circumferential Reduction of Abdomen Areahttps://practicaldermatology.com/news/btl-vanquish-fda-cleared-for-circumferential-reduction-of-abdomen-area/2458926/BTL Industries received FDA clearance of its BTL Vanquish device for circumferential reduction of the abdomen area. BTL Vanquish uses a panel array that emits selective RF energy with the largest spot size in the industry t
- Research Identifies Gene Linked to Melanoma Growth, Worse Outcomeshttps://practicaldermatology.com/news/research-identify-gene-linked-to-melanoma-growth-worse-outcomes/2458925/High levels of a specific protein linked to gene expression are associated with worse outcomes in melanoma, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published online in the journal Molecular Cell. Research shows that the protein, called H2A.Z.
- Investigational Foam May Offer Itch Relief for Psoriasis Patientshttps://practicaldermatology.com/news/investigational-foam-may-offer-itch-relief-for-psoriasis-patients/2458931/An investigational aerosol foam may provide rapid itch relief as well as improvements in itch-related sleep loss for patients with psoriasis, according to new data presented at the recent World Congress of Dermatology. According to the Phase 3 clinical trial, 426 psoriasis patients were split int
- NIH Funding Often Does Not Match Disease Burden for Dermatologic Conditionshttps://practicaldermatology.com/news/nih-funding-often-does-not-match-disease-burden-for-dermatologic-conditions/2458930/A new analysis of funding prioritization by the National Institutes of Health for skin disease offers a glimpse of cutaneous skin disease on a national level, with some disease states being possibly underfunded. Examining the relationship between dermatologic research funding and skin disease bur
- Galderma Introduces ASPIRE Loyalty Program for the Aesthetic Industryhttps://practicaldermatology.com/news/galderma-introduces-aspire-loyalty-program-for-the-aesthetic-industry/2458936/Galderma launched ASPIRE Galderma Rewards, a new loyalty program for its aesthetic brands. ASPIRE is unique in that it serves both both US healthcare professionals and consumers in one integrated program. ASPIRE rewards its members with significant savings across the entire aesthetic prod
- The American Academy of Dermatology Elects New Officers and Board Membershttps://practicaldermatology.com/news/the-american-academy-of-dermatology-elects-new-officers-and-board-members/2458941/The American Academy of Dermatology (AAD) announced the results of its annual election. The newly elected officers and board members will lead the AAD, which represents more than 19,000 physicians. These officers and board members also will hold the same positions for the American Academy of Derm
- ASDS Releases Consensus Recommendations on Basal Cell Carcinomahttps://practicaldermatology.com/news/asds-releases-consensus-recommendations-on-basal-cell-carcinoma/2458947/An expert group of dermatologic surgeons appointed by the American Society for Dermatologic Surgery (ASDS) Board of Directors has developed the first-ever consensus recommendations on the treatment and management of basal cell carcinoma (BCC). According to the ASDS, the document is intend
- Galderma to Enter Nutraceutical Markethttps://practicaldermatology.com/news/galderma-to-enter-nutraceutical-market/2458954/Galderma entred into the nutraceutical market through the acquisition of certain assets of Inneov Group. Relevant Inneov products are marketed under the brand names Nutri-Care D, Duocap, Densilogy, Densilogy Men, Fermete, Fermete Aox, Firmness, Pre-Hyaluron 465, Solar and Sun Sensitivity.
- AcneCareMD Website Launcheshttps://practicaldermatology.com/news/acnecaremd-website-launches/2458957/Jamie Altman, MD, owner and president of Aesthetic Dermatology Associates, PC, in Media and Paoli, PA, launched AcneCareMD.com, a secure telemedicine website to provide acne care to patients across Pennsylvania via
- Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agenthttps://practicaldermatology.com/news/provectus-opens-phase-3-trial-enrollment-for-investigational-melanoma-agent/2458965/Provectus Biopharmaceuticals, Inc. has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The study is an international multicenter, open-label, randomized controlled trial of single-agent intralesional PV-10 versus systemic chemother